Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, and Efficacy of Once Weekly Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone, in Transplant-ineligible Multiple Myeloma Patients Non-responsive to a Bortezomib Based Induction

Next Previous
Search
Trial Profile

Safety, Tolerability, and Efficacy of Once Weekly Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone, in Transplant-ineligible Multiple Myeloma Patients Non-responsive to a Bortezomib Based Induction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Anticoagulants
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms KyDaR

    • Most Recent Events

    • 13 Dec 2022 Results assessing the safety and efficacy of a quadruple salvage regimen of carfilzomib, lenalidomide, dexamethasone, daratumumab (KRD-D) in myeloma Pts and to identify molecular pathways of refractoriness based on transcriptional signatures with functional high presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 26 Jan 2022 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top